Foghorn Therapeutics Inc (FHTX) FinancialsFHTXFoghorn Therapeutics Inc

Evaluating the bottom line, Foghorn Therapeutics Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -54.78%, while the net margin is -44.74%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively FHTX converts its operational activities into shareholder value.

In the context of the broader market, FHTX competes directly with industry leaders such as HURA and ARMP. With a market capitalization of $113.14M, it holds a leading position in the sector. When comparing efficiency, FHTX's gross margin of 100.00% stands against HURA's N/A and ARMP's 100.00%. Such benchmarking helps identify whether Foghorn Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Foghorn's recent earnings report showed a Q2 GAAP EPS of -$0.10, beating expectations by $0.14, and revenue growth of 111.8% year-over-year, reaching $16.1 million. However, the company has reported consistent net losses, with a net income of -$7.19 million in Q2 2026, indicating ongoing financial challenges despite revenue growth.